Neumora Therapeutics, Inc. Common Stock

NMRA · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$56,755-$52,731-$67,992-$58,819
Dep. & Amort.$23$19$157$157
Deferred Tax$0$0$0$0
Stock-Based Comp.$5,980$7,165$9,324$9,903
Change in WC$4,483-$7,604-$525-$1,356
Other Non-Cash-$364$747-$412-$225
Operating Cash Flow-$46,633-$52,404-$59,448-$50,340
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$84$0$0
Inv. Purchases$0-$39,379-$44,385-$106,899
Inv. Sales/Matur.$51,246$68,796$88,545$8,100
Other Inv. Act.$71$896$0$0
Investing Cash Flow$51,317$30,397$44,160-$98,799
Financing Activities
Debt Repay.-$136$18,398$0$0
Stock Issued$0$59$0$13,694
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$1,879
Financing Cash Flow-$136$18,457$0$15,573
Forex Effect$0$0$0$0
Net Chg. in Cash$4,548-$3,550-$15,288-$133,566
Supplemental Information
Beg. Cash$124,523$128,073$143,361$276,927
End Cash$129,071$124,523$128,073$143,361
Free Cash Flow-$46,649-$52,404-$59,448-$50,340